California-based BioCardia Inc., a clinical-stage regenerative medicine firm, is in the development stage of creating cellular and cell-derived treatments for pulmonary and cardiovascular diseases. BioCardia's flagship product, CardiAMP, is an autologous mononuclear cell therapy system that serves as the primary therapeutic candidate intended for heart failure and chronic myocardial ischemia, as well as an allogeneic cell therapy for cardiac and pulmonary disease. Additionally, the company is currently engaged in developing an allogeneic cells therapeutic platform, an investigative culture-expanded bone marrow derived mesenchymal cell therapy that has reached Phase I/II trials for ischemic heart failure treatment. BioCardia provides the Helix biotherapeutic delivery system, which is equipped to penetrate the heart muscle with a helical needle from within the heart, as well as Morph deflectable guides and sheaths.